<DOC>
	<DOCNO>NCT00494559</DOCNO>
	<brief_summary>People diabetes mellitus prone coronary heart disease , stroke , peripheral vascular disease , diabetes mellitus regard independent risk factor progression coronary artery disease . Several study report diabetes increase risk cardiovascular mortality men woman . With introduction drug-eluting stent ( DESs ) , angiographic rate restenosis later month reduce dramatically several study . However , even DESs , diabetic patient show increased rate restenosis late loss index compare nondiabetic patient . Diabetes consider predictor poor prognosis percutaneous coronary intervention drug-eluting stent . Long-term clinical angiographic outcome percutaneous coronary intervention ( PCI ) drug-metal stent ( DESs ) demonstrate worse diabetic patient compare nondiabetic patient . In era DESs , study demonstrate clinical angiographic outcome diabetic patient zotarolimus-eluting stent implantation use intravascular ultrasound ( IVUS ) . Pioglitazone use treatment diabetic patient . Thiazolidinediones increase insulin sensitivity show favorable effect blood glucose level lipid profile . The effect pioglitazone neointima volume inflammatory marker compare prospective manner zotarolimus-eluting stent implantation . The purpose prospective , randomize , single blind trial compare effect pioglitazone inflammatory marker neointima volume use IVUS diabetic patient .</brief_summary>
	<brief_title>The Effect Pioglitazone Neointima Volume Inflammatory Markers</brief_title>
	<detailed_description>With introduction DES , angiographic rate restenosis decrease dramatically less prominently diabetic patient . Even era DES , diabetes remains significant predictor coronary restenosis especially case small baseline post PCI vessel size , longer stent length , current smoker , high level CRP . Restenosis remain main clinical angiographic concern DES implantation especially diabetic patient . Diabetes known major risk factor in-stent restenosis DES implantation . 1 . Primary end point : Comparison pioglitazone placebo 8 month follow-up neointima volume intravascular ultrasound ( IVUS ) . 2 . Secondary end point : Comparison pioglitazone placebo change level inflammatory marker ( hsCRP , IL-6 , TNF-α , adiponectin ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Neointima</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Age : 18 year Gender eligible study : Diabetic patient either previously diagnose newly find diabetes . Fasting blood glucose ≥ 126 mg/dl PP2 blood glucose ≥ 200 mg/dl newly find diabetes . Patients significant de novo coronary artery disease ( diameter stenosis &gt; 70 % ) require stent implantation ( angina pectoris and/or exerciseinduced ischemia ) . Patients informed consent . Acute STsegment elevation myocardial infarction ( MI ) CTO lesion Left main lesion Diabetic patient use thiazolidinediones within 3 month Previous history PCI bypass surgery Patients contraindication treatment thiazolidinediones Pregnant lactate patient Chronic alcohol drug abuse Hepatic dysfunction Renal dysfunction Heart failure ( EF &lt; 50 % ) Expected life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>restenosis</keyword>
</DOC>